The short answer
Classic Hodgkin lymphoma is planned around three groups: early favorable, early unfavorable, and advanced. Combination chemotherapy is the backbone in all three, with brentuximab vedotin or nivolumab added in the heavier groups and checkpoint inhibitors leading at relapse.
NCI sorts classic Hodgkin lymphoma into early favorable, early unfavorable and advanced, and the group drives the plan.
Adverse early-stage factors include a large mediastinal mass, B symptoms, a raised sedimentation rate and three or more node areas.
Early unfavorable disease may add brentuximab vedotin; advanced disease may add nivolumab or brentuximab vedotin to chemotherapy.
At relapse NCI lists pembrolizumab or nivolumab with or without chemotherapy, sometimes followed by stem cell transplant.
Choose how you want to understand this
The full explanation.
Start with your risk group
Hodgkin lymphoma treatment is planned around a risk group. The three groups are early favorable, early unfavorable, and advanced. This grouping combines your stage and your B symptoms. B symptoms means fever, drenching night sweats, or weight loss with no clear cause. It also factors in whether any mass is unusually large. Ask which group you fall into and why, since it drives everything else.
Early favorable disease
This group usually gets combination chemotherapy. The most common regimen is called ABVD. Radiation to the original tumor area is sometimes added. For people who cannot tolerate chemotherapy, radiation alone is an option. Cure rates in this group are high.
Early unfavorable disease
This group needs slightly more intensive treatment. Options include the same chemotherapy with radiation. A newer combination adds brentuximab vedotin. This drug delivers chemotherapy directly to CD30, a marker on Hodgkin lymphoma cells.
Advanced disease
Stage III or IV disease is treated with combination chemotherapy. Your team may add nivolumab, an immunotherapy drug, or brentuximab vedotin to the regimen. A PET scan partway through treatment often guides whether the plan should change.
If it comes back
Relapsed Hodgkin lymphoma has real options. Immunotherapy with pembrolizumab or nivolumab, with or without chemotherapy, is one path. It is sometimes followed by an autologous stem cell transplant. In this procedure, your own blood-forming cells are collected, then given back after high-dose treatment. Brentuximab vedotin, alone or with nivolumab, is another option. For people over 60, chemotherapy plus radiation may be used instead of transplant.
Weighing benefits and harms
ABVD-based chemotherapy has decades of track record and high cure rates. But it can cause nausea and low blood counts. Rarely, it can affect the lungs or heart, which is worth discussing before you start. Brentuximab vedotin adds nerve-related side effects, such as tingling in the hands or feet, to the picture. Immunotherapy drugs like nivolumab and pembrolizumab can cause immune-related side effects. Here, the immune system attacks healthy organs instead of just the cancer. These can appear weeks after a dose, and need prompt reporting. Stem cell transplant is intensive and requires weeks of close monitoring, often with a hospital stay.
What to ask your team
- What is my risk group, and how was it determined?
- Why was this specific chemotherapy regimen chosen over the others?
- Will a mid-treatment PET scan change my plan, and when is it scheduled?
- What side effects need same-day attention versus routine reporting?
- If this treatment does not work, what would the next step be?
- Should fertility preservation be discussed before I start?
When to get help sooner
Every option above lowers blood counts or stirs up the immune system, so a few things need a call rather than a wait.
- Call 911 or go to an emergency department if you have sudden or severe difficulty breathing, chest pain, or a heart that is racing. Bleomycin, the B in ABVD, can injure the lungs, and the NHS puts sudden breathlessness or chest pain in the emergency group because of the risk of a clot in the lung. Also go straight in for bleeding that will not stop after a few minutes, or for a bad headache, confusion, or sudden trouble seeing.
- Call your care team immediately, at any hour, if you have a temperature of 100.4°F (38°C) or higher, the figure CDC uses, or chills, at any point after chemotherapy. ABVD and the regimens that follow it flatten your neutrophils, and the CDC treats a fever during chemotherapy as a medical emergency. Be seen the same hour, not the same day, so if you cannot reach the team quickly, go to an emergency department and tell them you are on chemotherapy. Do not take anything to bring the temperature down first, since NCI warns that masks the sign your team is watching for.
- Call your care team the same day if you have a new cough or sore throat, sores or white coating in the mouth, redness or swelling where a line enters the skin, or diarrhea. On nivolumab or pembrolizumab, the same applies to new breathlessness, watery or bloody stools, or yellowing of the eyes or skin, since immune reactions can start weeks after a dose.
- Call your care team within a day or two if you notice bruises with no injury, tiny purple or red dots on the skin, nosebleeds or bleeding gums, or numbness and tingling in the hands or feet on brentuximab vedotin. Also report drenching night sweats or a lump that comes back.
Sources
- National Cancer Institute — Hodgkin Lymphoma Treatment (PDQ).
- CDC — Watch Out for Fever (Preventing Infections in Cancer Patients).
- National Cancer Institute — Hodgkin Lymphoma Treatment (PDQ) Health Professional Version.
- NCI — Infection and Neutropenia during Cancer Treatment
- NCI — Bleeding and Bruising (Thrombocytopenia) and Cancer Treatment
- NHS — Pulmonary embolism
Words to know
Tap any term to see what it means.
Common questions
What is a risk group, and why does mine matter?
Hodgkin lymphoma treatment is planned around three risk groups: early favorable, early unfavorable, and advanced. The grouping combines your stage, your B symptoms, and whether any mass is unusually large. It drives everything else, so ask which group you are in and why.
What are B symptoms?
Fever, drenching night sweats, or weight loss with no clear cause. They feed directly into which risk group you are placed in.
How is early disease usually treated?
Early favorable disease usually gets combination chemotherapy, most commonly a regimen called ABVD, sometimes with radiation to the original tumor area. Radiation alone is an option for people who cannot tolerate chemotherapy, and cure rates in this group are high. Early unfavorable disease needs slightly more intensive treatment, and a newer combination adds brentuximab vedotin.
Why is a scan done partway through treatment?
In advanced disease, a PET scan partway through often guides whether the plan should change. Ask when yours is scheduled and what kind of result would lead to a different regimen.
What are the options if it comes back?
There are real ones. Immunotherapy with pembrolizumab or nivolumab, with or without chemotherapy, is one path, sometimes followed by an autologous stem cell transplant using your own collected blood-forming cells. Brentuximab vedotin, alone or with nivolumab, is another. For people over 60, chemotherapy plus radiation may be used instead of transplant.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-13 what this meansLast updated: 2026-08-20Next planned review: 2027-01-22
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share